KRAS and cancer: Interestingly, Nichols and colleagues demonstrated that in several MAPK pathway mutant cancer-driven cancers, including non-V600E, class 3 BRAF mutant-driven cancers, NF1 deletion-driven cancers, and KRAS G12C mutant cancers, SHP2 inhibition is effective at inhibiting downstream MEK/ERK signaling (Nichols et al., 2018).